Adenovirus serotype 26 and serotype 35 filovirus vaccines

US9701718B2 · kind B2 · utility

Assignees

• Janssen Vaccines & Prevention B.V.
• THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · US

Inventors

• Nancy Sullivan · Kensington, US
• Gary J. Nabel · Cambridge, US
• Clement Asiedu · Olney, US
• Cheng Cheng · Bethesda, US
• Maria Grazia Pau · Leiden, NL
• Jaap Goudsmit · Amsterdam, NL

Key dates

• Filing date: Dec 14, 2011
• Grant date: Jul 11, 2017
• Expiry date: Dec 14, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/14134
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided are recombinant adenovirus vectors (serotype 26 and serotype 35) encoding filovirus antigens. The adenovirus vectors can be used to induce protective immune responses against filovirus infection.